Indian frankincense · Salai guggal · Boswellin · 5-Loxin · Aflapin
450 mg · vegan · gluten-free · 60 caps
Affiliate link · we earn from qualifying purchases. No paid placements.
Boswellia serrata is a tree native to India that produces a resin known as Indian frankincense. The resin contains boswellic acids, particularly acetyl-11-keto-beta-boswellic acid (AKBA), which inhibit 5-lipoxygenase (5-LOX), a key enzyme in inflammatory leukotriene synthesis.
Boswellic acids inhibit 5-LOX, reducing synthesis of pro-inflammatory leukotrienes. They also modulate NF-kB signaling, reduce matrix metalloproteinase activity (protecting cartilage), and may improve blood supply to inflamed joints.
Adults with osteoarthritis, individuals with inflammatory joint conditions, those seeking alternatives to NSAIDs, people interested in Ayurvedic botanicals.
People taking anticoagulants (potential interaction), those with bleeding disorders, pregnant or breastfeeding women (traditional contraindication), children.
Pick a depth — minimum to maximal coverage
No full stack configured.
Click individual supplement pills above to buy each on Amazon India.
✓ Morning for consistent anti-inflammatory support throughout the day
✓ Food improves absorption and reduces GI discomfort
Boswellic acids inhibit 5-LOX, reducing synthesis of pro-inflammatory leukotrienes.
Each bar = one cited trial. Effect varies by methodology, dose, and population.
Elevated inflammation cohort (n≈70)
Target hsCRP <1.0 mg/L for low cardiovascular risk.
see study
→ 5-Loxin 100 mg/day improved WOMAC pain by 46% and function by 42% vs placebo; reduced MMP-3 (N=75, 90 days)
see study
→ Boswellia extract reduced knee pain, improved walking distance, and decreased frequency of swelling (N=30, 8 weeks)
see study
→ Aflapin 100 mg/day improved pain and function within 5 days; sustained at 30 and 60 days (N=60)
B · Consistent efficacy across multiple RCTs; rapid onset (1–2 weeks); well-characterized mechanism; proprietary extracts (5-Loxin, Aflapin) show enhanced activity; excellent safety profile vs NSAIDs
A plain-English read of the literature behind this supplement. Not a clinical recommendation.
Key citations: PMID 21491461 (Sengupta 2011, OA RCT n=60), PMID 17982690 (Sontakke 2007, AKBA mechanism review), PMID 26022965 (Gupta 2011, 5-LOX inhibition study).
How to use Boswellia Serrata specifically for joint pain — the right dose, timing, blood markers to track, and how to know if it is working.
A clinical evidence review of Boswellia Serrata — RCT data, effect sizes, evidence grade, and what the numbers mean for your specific situation.
Everything you need to know about Boswellia Serrata — mechanism, dose, safety, buying guide for India, and what the research actually says.
SacredBod's longer take on Boswellia Serrata — context the structured blocks above don't capture.
Boswellia serrata is the anti-inflammatory botanical with the strongest clinical evidence for osteoarthritis. Unlike turmeric, which has promising but heterogeneous trial data, or ginger, which is better supported for nausea than joint pain, boswellia has demonstrated consistent efficacy across multiple randomized controlled trials with a well-characterized mechanism: inhibition of 5-lipoxygenase (5-LOX), the enzyme that produces pro-inflammatory leukotrienes. This specificity distinguishes it from broad-spectrum anti-inflammatories and may explain its favorable safety profile.
The 5-Loxin trial established both efficacy and speed. Sengupta and colleagues (2008, Arthritis Research & Therapy, PMID 19134194) randomized 75 patients with knee osteoarthritis to 5-Loxin (a proprietary extract enriched in AKBA) 100 mg daily, 250 mg daily, or placebo for 90 days. The 100 mg dose improved WOMAC pain scores by 46% and function scores by 42% compared to placebo. Notably, the improvement began within 7 days—a rapid onset that contrasts with the 4–12 weeks required for glucosamine. The 250 mg dose provided no additional benefit, establishing a clear dose ceiling. The trial also measured matrix metalloproteinase-3 (MMP-3), a cartilage-degrading enzyme, and found significant reduction in the 5-Loxin group.
The traditional use is validated by modern trials. Kimmatkar and colleagues (2003, Phytomedicine, PMID 12614509) conducted an early randomized trial in 30 knee osteoarthritis patients, testing a standardized boswellia extract. After 8 weeks, the boswellia group showed significant reductions in knee pain, improved walking distance, and decreased swelling frequency. This trial, while small, demonstrated that traditional Ayurvedic use had pharmacological substance. Vishal and colleagues (2011, International Journal of Medical Sciences, PMID 21442477) introduced Aflapin, another proprietary extract, and found pain and function improvements within 5 days—confirming the rapid onset seen with 5-Loxin.
The safety advantage over NSAIDs is meaningful. Boswellia does not inhibit COX-1, so it does not cause gastric ulceration, bleeding, or cardiovascular risks associated with traditional NSAIDs. Side effects are mild and primarily gastrointestinal. However, the anticoagulant potential requires caution for those on blood thinners. The honest framing: boswellia is a well-validated anti-inflammatory botanical with rapid onset, consistent efficacy in osteoarthritis, and a mechanism distinct from NSAIDs. It is appropriate for individuals seeking anti-inflammatory joint support without the risks of pharmaceutical NSAIDs.
Peptides are physician-only. Tell us a bit and we'll route you to the right specialist.
